Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- OPF to Exclusively Market 3 Plasma Volume Expanders in Japan
May 24, 2013
- Daiichi Sankyo: Ranbaxy Former Shareholders Hid Critical Information
May 24, 2013
- Japan’s 1st Western Herbal Medicine Antistax to Hit Shelves in June: SSP
May 24, 2013
- Vital KSK HD Reports Single-Product, Single-Price Agreements Reached with Nearly 100% of Customers by End of March
May 24, 2013
- Pfizer Discontinues PIII Study of Inotuzumab Ozogamicin for NHL
May 24, 2013
- About 80% of Drug Makers Have Introduced Web Seminars; Cost-savings, Increased Sales Reported
May 24, 2013
- Maker FTC’s Provisional GL Prohibits Offering of Refreshments, Bentos at Web Seminars When There is Only 1 Participant from a Single Medical Institution
May 24, 2013
- Zeria Will Launch FD Treatment in June, Finding Patients Key, President Ibe Says
May 23, 2013
- Announcement: Sales Force Effectiveness Japan 2013 to Be Held on July 16, 17
May 23, 2013
- Meiji Seika Pharma’s Generic Sales Seen Reaching 30 Billion Yen a Year Ahead of Schedule
May 23, 2013
- Once-Monthly Injectable Abilify Reduces Total Psychiatric Hospitalization Rates following Disease Relapse: Otsuka, Lundbeck
May 23, 2013
- Efficacy of Major Depressive Disorder Treatment Vortioxetine Shown in Three of Four PIII Studies: Takeda and Lundbeck
May 23, 2013
- AZ Oncology Division to Provide Information Based on Patients’ Lifestyle
May 22, 2013
- Apo Plus Station Eyes Sales Force of 300 for Established Products
May 22, 2013
- Domestic Sales of Ethical Drugs Rose 0.3% to 9,560.1 Billion Yen in FY2012: IMS Japan
May 22, 2013
- GSK Shares Clinical Trial Data with Researchers before Statistical Analysis
May 22, 2013
- Major Dispensing Pharmacy Chain Operators Expect Record High Sales and Profits in FY2013
May 21, 2013
- Five Major Dispensing Pharmacy Chain Operators’ Profits Down Due to NHI Price Revision
May 21, 2013
- Allegra AGs Pitched as Affordable Original Drugs with Production by Sanofi
May 21, 2013
- ALS Treatment Ozanezumab Designated as Orphan Drug: GSK
May 21, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…